Artificial intelligence is increasingly reshaping biotech research and healthcare. New AI models have enabled advances in traditionally undruggable targets such as intrinsically disordered proteins, expanding druggable space with novel binder designs, as reported by the Baker lab. Automated platforms like Chemify’s ‘Chemifarm’ integrate AI, robotics, and chemical synthesis, dramatically reducing discovery timelines from concept to compound. Quantum computing is poised to tackle complex biopharma challenges, promising to transform drug discovery processes. Patient research indicates openness to AI in healthcare contingent on preservation of doctor-patient interaction and transparency. Furthermore, computational tools underpin biomarker discovery and precision medicine development across immunology and oncology.